Redox metabolism abnormalities in autistic children associated with mitochondrial disease

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Frye, R E ^a,b   Delatorre, R ^c   Taylor, H ^d   Slattery, J ^a,b   Melnyk, S ^a,b   Chowdhury, N ^a   James, S J ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d Texas Institute of Rehabilitation Research   (United States)

Author keywords

autism; endophenotypes; inflammation; mitochondrial disease; oxidative stress

Indexed keywords

3 CHLOROTYROSINE; 3 NITROTYROSINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIOXIDANT; CARNITINE; CYANOCOBALAMIN; FISH OIL; FOLIC ACID; GLUTATHIONE DISULFIDE; MELATONIN; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; VITAMIN B GROUP; 3-CHLOROTYROSINE; 3-NITROTYROSINE; BIOLOGICAL MARKER; GLUTATHIONE; TYROSINE; DRUG DERIVATIVE;

ADAPTIVE BEHAVIOR; AGE; ARTICLE; AUTISM; BLOOD ANALYSIS; CHILD; CHILD BEHAVIOR; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEVELOPMENT; CONTROLLED STUDY; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; GLUTATHIONE METABOLISM; HUMAN; INTERPERSONAL COMMUNICATION; LANGUAGE; LANGUAGE DEVELOPMENT; LINGUISTICS; MALE; METABOLISM; OXIDATIVE STRESS; PRESCHOOL CHILD; QUESTIONNAIRE; RATING SCALE; RECEPTOR UPREGULATION; SCHOOL CHILD; SKILL; SOCIAL ADAPTATION; SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; NEUROPSYCHOLOGICAL TEST; OXIDATION REDUCTION REACTION;

AGE FACTORS; BIOLOGICAL MARKERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; FEMALE; GLUTATHIONE; HUMANS; LANGUAGE DEVELOPMENT; MALE; MITOCHONDRIAL DISEASES; NEUROPSYCHOLOGICAL TESTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; TYROSINE;

EID: 84879941151     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.51     Document Type: Article

References (77)

1. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association: Washington, DC, 1994.
2. Rice C. Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ 2009; 58: 1-20.
3. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med 2013; 15: 399-407.
4. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res 2011; 69(5 Pt 2): 41R-47RR.
5. Buie T, Campbell DB, Fuchs GJ III, Furuta GT, Levy J, Vandewater J et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 2010; 125(Suppl 1): S1-18.
6. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 947-956. (Pubitemid 44905454)
7. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 2011; 25: 40-45.
8. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012; 17: 389-401.
9. Ming X, Brimacombe M, Chaaban J, Zimmerman-Bier B, Wagner GC. Autism spectrum disorders: concurrent clinical disorders. J Child Neurol 2008; 23: 6-13.
10. Herbert MR. Autism: a brain disorder or a disorder that affects the brain. Clin Neuropsych 2005; 2: 354-379.
11. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2012; 17: 290-314.
12. Frye RE. Biomarker of abnormal energy metabolism in children with autism spectrum disorder. N Am J Med Sci 2012; 5: 141-147.
13. Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C, Wong S, Hertz-Picciotto I et al. Mitochondrial dysfunction in autism. JAMA 2010; 304: 2389-2396.
14. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011; 68: 1095-1102.
15. Frye RE, Naviaux RK. Autistic disorder with complex IV overactivity: a new mitochondrial syndrome. J Ped Neurol 2011; 9: 427-434.
16. Graf WD, Marin-Garcia J, Gao HG, Pizzo S, Naviaux RK, Markusic D et al. Autism associated with the mitochondrial DNA G8363A transfer RNALys mutation. J Child Neurol 2000; 15: 357-361. (Pubitemid 30418050)
17. Frye RE. Novel cytochrome b gene mutations causing mitochondrial disease in autism. J Ped Neurol 2011; 10: 35-40.
18. Herbert MR, Russo JP, Yang S, Roohi J, Blaxill M, Kahler SG et al. Autism and environmental genomics. Neurotoxicology 2006; 27: 671-684. (Pubitemid 44232987)
19. Ashwood P, Van de Water J. Is autism an autoimmune disease? Autoimmun Rev 2004; 3: 557-562.
20. Bayona-Bafaluy MP, Lopez-Gallardo E, Montoya J, Ruiz-Pesini E. Maternally inherited susceptibility to cancer. Biochim Biophys Acta 2011; 1807: 643-649.
21. Nishigaki Y, Fuku N, Tanaka M. Mitochondrial haplogroups associated with lifestyle-related diseases and longevity in the Japanese population. Geriatr Gerontol Int 2010; 10(Suppl 1): S221-S235.
22. Fowler BA, Woods JS. Ultrastructural and biochemical changes in renal mitochondria during chronic oral methyl mercury exposure: the relationship to renal function. Exp Mol Pathol 1977; 27: 403-412. (Pubitemid 8234400)
23. Shenker BJ, Guo TL, O I, Shapiro IM. Induction of apoptosis in human T-cells by methyl mercury: temporal relationship between mitochondrial dysfunction and loss of reductive reserve. Toxicol Appl Pharmacol 1999; 157: 23-35. (Pubitemid 29250250)
24. Goyer RA. Toxic and essential metal interactions. Annu Rev Nutr 1997; 17: 37-50. (Pubitemid 27328791)
25. Pourahmad J, Mihajlovic A, O'Brien PJ. Hepatocyte lysis induced by environmental metal toxins may involve apoptotic death signals initiated by mitochondrial injury. Adv Exp Med Biol 2001; 500: 249-252. (Pubitemid 34107010)
26. Hiura TS, Li N, Kaplan R, Horwitz M, Seagrave JC, Nel AE. The role of a mitochondrial pathway in the induction of apoptosis by chemicals extracted from diesel exhaust particles. J Immunol 2000; 165: 2703-2711. (Pubitemid 30660720)
27. Wong PW, Garcia EF, Pessah IN. ortho-substituted PCB95 alters intracellular calcium signaling and causes cellular acidification in PC12 cells by an immunophilin-dependent mechanism. J Neurochem 2001; 76: 450-463. (Pubitemid 32098022)
28. Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 2007; 100: 1469-1479. (Pubitemid 46376213)
29. Yamano T, Morita S. Effects of pesticides on isolated rat hepatocytes, mitochondria, and microsomes II. Arch Environ Contam Toxicol 1995; 28: 1-7.
30. Samavati L, Lee I, Mathes I, Lottspeich F, Huttemann M. Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase. J Biol Chem 2008; 283: 21134-21144.
31. Vempati UD, Diaz F, Barrientos A, Narisawa S, Mian AM, Millan JL et al. Role of cytochrome C in apoptosis: increased sensitivity to tumor necrosis factor alpha is associated with respiratory defects but not with lack of cytochrome C release. Mol Cell Biol 2007; 27: 1771-1783.
32. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003; 107: 1418-1423. (Pubitemid 36350742)
33. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, Andersen JK et al. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007; 149: 917-930. (Pubitemid 350130291)
34. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcoholinduced defect. Am J Physiol 1997; 273(1 Pt 1): G7-G17.
35. Koopman WJ, Nijtmans LG, Dieteren CE, Roestenberg P, Valsecchi F, Smeitink JA et al. Mammalian mitochondrial complex I: biogenesis, regulation, and reactive oxygen species generation. Antioxid Redox Signal 2010; 12: 1431-1470.
36. Distelmaier F, Koopman WJ, van den Heuvel LP, Rodenburg RJ, Mayatepek E, Willems PH et al. Mitochondrial complex I deficiency: from organelle dysfunction to clinical disease. Brain 2009; 132(Pt 4): 833-842.
37. Chinta SJ, Andersen JK. Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease. Free Radic Res 2011; 45: 53-58.
38. Wiesner RJ, Zsurka G, Kunz WS. Mitochondrial DNA damage and the aging process: facts and imaginations. Free Radic Res 2006; 40: 1284-1294. (Pubitemid 44698278)
39. Ghanizadeh A, Akhondzadeh S, Hormozi M, Makarem A, Abotorabi-Zarchi M, Firoozabadi A. Glutathione-related factors and oxidative stress in autism, a review. Current medicinal chemistry 2012; 19: 4000-4005.
40. Naviaux RK. Oxidative shielding or oxidative stress? J Pharmacol Exp Ther 2012; 342: 608-618.
41. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med 2012; 52: 2128-2141.
42. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology 2008; 29: 190-201.
43. James SJ, Rose S, Melnyk S, Jernigan S, Blossom S, Pavliv O et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J 2009; 23: 2374-2383.
44. Melnyk S, Fuchs GJ, Schulz E, Lopez M, Kahler SG, Fussell JJ et al. Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. J Autism Dev Disord 2012; 42: 367-377.
45. Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry 2012; 2: e134.
46. Chauhan A, Audhya T, Chauhan V. Brain region-specific glutathione redox imbalance in autism. Neurochem Res 2012; 37: 1681-1689.
47. Napoli E, Wong S, Giulivi C. Evidence of reactive oxygen species-mediated damage to mitochondrial DNA in children with typical autism. Mol Autism 2013; 4: 2.
48. Damodaran LP, Arumugam G. Urinary oxidative stress markers in children with autism. Redox Rep 2011; 16: 216-222.
49. Ali A, Waly MI, Al-Farsi YM, Essa MM, Al-Sharbati MM, Deth RC. Hyperhomocysteinemia among Omani autistic children: a case-control study. Acta Biochim Pol 2011; 58: 547-551.
50. Waly MI, Hornig M, Trivedi M, Hodgson N, Kini R, Ohta A et al. Prenatal and postnatal epigenetic programming: implications for GI, immune, and neuronal function in autism. Autism Res Treat 2012; 2012: 190930.
51. James SJ, Shpyleva S, Melnyk S, Pavliv O, Pogribny IP. Complex epigenetic regulation of Engrailed-2 (EN-2) homeobox gene in the autism cerebellum. Transl Psychiatry 2013; 3: e232.
52. Finkelstein JD. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin Chem Lab Med 2007; 45: 1694-1699. (Pubitemid 350232969)
53. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev 2008; 13: 216-226.
54. Mitochondrial Medicine Society's Committee on DHaas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 2008; 94: 16-37.
55. Munnich A, Rustin P. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet 2001; 106: 4-17.
56. Wong LJ. Pathogenic mitochondrial DNA mutations in protein-coding genes. Muscle Nerve 2007; 36: 279-293.
57. Wong LJ, Cobb BR, Chen TJ. Molecular analysis of mitochondrial DNA point mutations by polymerase chain reaction. Methods Mol Biol 2006; 336: 135-143.
58. Bai RK, Perng CL, Hsu CH, Wong LJ. Quantitative PCR analysis of mitochondrial DNA content in patients with mitochondrial disease. Ann N Y Acad Sci 2004; 1011: 304-309.
59. Bai RK, Wong LJ. Simultaneous detection and quantification of mitochondrial DNA deletion(s), depletion, and over-replication in patients with mitochondrial disease. J Mol Diagn 2005; 7: 613-622.
60. Kirby DM, Thorburn DR, Turnbull DM, Taylor RW. Biochemical assays of respiratory chain complex activity. Methods Cell Biol 2007; 80: 93-119.
61. Roe CR, Roe DS. Recent developments in the investigation of inherited metabolic disorders using cultured human cells. Mol Genet Metab 1999; 68: 243-257. (Pubitemid 29501097)
62. Morava E, van den Heuvel L, Hol F, de Vries MC, Hogeveen M, Rodenburg RJ et al. Mitochondrial disease criteria: diagnostic applications in children. Neurology 2006; 67: 1823-1826. (Pubitemid 44900760)
63. Sparrow S, Cicchetti D, Balla D. Vineland Adaptive Behavior Scales. 2nd edn Minneapolis, MN, 2005.
64. Zimmerman IL, Steiner VG, Pond RE. Preschool Language Scale. 4th edn Harcourt Assessment: San Antonio, TX, 2002.
65. Brownell R. Expressive One-Word Picture Vocabulary Test Manual. Academic Therapy Publications: Novato, CA, 2000.
66. Constantino JN. The Social Responsiveness Scale. Western Psychological Services: Los Angeles, 2002.
67. Melnyk S, Pogribna M, Pogribny I, Hine RJ, James SJ. A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection. J Nutr Biochem 1999; 10: 490-497. (Pubitemid 29378307)
68. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
69. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004; 58: 39-46. (Pubitemid 38117047)
70. Milton VJ, Sweeney ST. Oxidative stress in synapse development and function. Dev Neurobiol 2012; 72: 100-110.
71. Ristow M, Schmeisser S. Extending life span by increasing oxidative stress. Free Radic Biol Med 2011; 51: 327-336.
72. Fato R, Bergamini C, Leoni S, Strocchi P, Lenaz G. Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem Res 2008; 33: 2487-2501.
73. Edmonds JL, Kirse DJ, Kearns D, Deutsch R, Spruijt L, Naviaux RK. The otolaryngological manifestations of mitochondrial disease and the risk of neurodegeneration with infection. Arch Otolaryngol Head Neck Surg 2002; 128: 355-362. (Pubitemid 34293142)
74. Shoffner J, Hyams L, Langley GN, Cossette S, Mylacraine L, Dale J et al. Fever plus mitochondrial disease could be risk factors for autistic regression. J Child Neurol 2010; 25: 429-434.
75. Frye RE, Rossignol DA. Treatments for mitochondrial dysfunction associated with autism spectrum disorders. J Ped Biochem 2012; 2: 241-249.
76. Lofthouse N, Hendren R, Hurt E, Arnold LE, Butter E. A review of complementary and alternative treatments for autism spectrum disorders. Autism Res Treat 2012; 2012: 870391.
77. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009; 21: 213-236.